Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roger Darioli

Showing results (31-40 of 35) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 35 results.
Angiology|April 5, 2008
Surrogate markers for atherosclerosis in overweight subjects with atherogenic dyslipidemia: the GEMS projectMyriam Genoud, Vincent Wietlisbach, François Feihl, et al.
AIDS (London, England)|September 28, 2002
Efficacy and safety of fluvastatin in hyperlipidemic protease inhibitor-treated HIV-infected patientsNicole Doser, Sandrine Kübli, Amalio Telenti, et al.
Annals of Internal Medicine|April 17, 2002
High risk for hyperlipidemia and the metabolic syndrome after an episode of hypertriglyceridemia during 13-cis retinoic acid therapy for acne: a pharmacogenetic studyNicolas Rodondi, Roger Darioli, Albert-Adrien Ramelet, et al.
Pharmacogenetics and Genomics|August 19, 2007
Contribution of 20 single nucleotide polymorphisms of 13 genes to dyslipidemia associated with antiretroviral therapyMireia Arnedo, Patrick Taffé, Roland Sahli, et al.
The Journal of Infectious Diseases|April 6, 2005
Modeling the influence of APOC3, APOE, and TNF polymorphisms on the risk of antiretroviral therapy-associated lipid disordersPhilip E Tarr, Patrick Taffé, Gabriela Bleiber, et al.
Pageof 4

Showing results (31-40 of 35) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 35 results.
Angiology|April 5, 2008
Surrogate markers for atherosclerosis in overweight subjects with atherogenic dyslipidemia: the GEMS projectMyriam Genoud, Vincent Wietlisbach, François Feihl, et al.
AIDS (London, England)|September 28, 2002
Efficacy and safety of fluvastatin in hyperlipidemic protease inhibitor-treated HIV-infected patientsNicole Doser, Sandrine Kübli, Amalio Telenti, et al.
Annals of Internal Medicine|April 17, 2002
High risk for hyperlipidemia and the metabolic syndrome after an episode of hypertriglyceridemia during 13-cis retinoic acid therapy for acne: a pharmacogenetic studyNicolas Rodondi, Roger Darioli, Albert-Adrien Ramelet, et al.
Pharmacogenetics and Genomics|August 19, 2007
Contribution of 20 single nucleotide polymorphisms of 13 genes to dyslipidemia associated with antiretroviral therapyMireia Arnedo, Patrick Taffé, Roland Sahli, et al.
The Journal of Infectious Diseases|April 6, 2005
Modeling the influence of APOC3, APOE, and TNF polymorphisms on the risk of antiretroviral therapy-associated lipid disordersPhilip E Tarr, Patrick Taffé, Gabriela Bleiber, et al.
Pageof 4